The BIA has submitted a letter to Guy Opperman MP as part of the Department for Work and Pensions' (DWP) consultation on Broadening the investment opportunities of defined contribution pension schemes.
Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025, the European Union’s flagship research and innovation funding programme.
Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, today announced a £4.8 million (c. $6.5 million) extension to its Series C financing, in addition to the £14 million secured in March 2025, bringing the total in the round to £18.8 million (c. $25.4 million).
With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.
In this blog, Katherine Powers, Life Sciences Senior Analyst at RSM US, and Max Stanyard, Life Sciences Senior Analyst at RSM UK, highlight the investment uncertainty in the UK-US life sciences ecosystem.
The UK’s life sciences and biotech sector has long been recognised for its scientific excellence, vibrant innovation and dynamic startup culture around the globe. In the past year, interest in our business ecosystem from international partners has markedly accelerated.
